)

Bristol-Myers Squibb Company (BMY) investor relations material
Bristol-Myers Squibb Company Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Market dynamics and access challenges
CAR T therapies have transformative potential but face adoption barriers due to delivery limitations in community practices and referral patterns, especially in the U.S.
France leads in CAR T adoption due to integrated healthcare systems, while the U.S. and other countries lag due to fragmented care and access issues.
Recent regulatory changes, such as reduced REMS requirements, are expected to improve patient access and reduce treatment burden.
Efforts are underway to expand CAR T delivery into community oncology centers, with early success in select locations.
Only 20% of eligible U.S. patients currently receive CAR T, highlighting significant growth potential.
Innovation and pipeline development
The pipeline includes best-in-class and first-in-class CAR Ts, such as GPRC5D (Orva-cel) and dual-targeting CARs for multiple myeloma, and CD19 Breyanzi for B-cell malignancies.
Orva-cel shows promising efficacy and safety in both BCMA-naive and BCMA-exposed patients, with pivotal data expected next year.
Dual-targeting CARs aim to address high unmet needs in newly diagnosed multiple myeloma, balancing efficacy and safety.
Investments are being made in off-the-shelf (allo) and in vivo CAR T platforms, with early clinical progress in autoimmune indications.
The company is pursuing basket trial designs to accelerate development across multiple autoimmune diseases.
Performance drivers and differentiation
Manufacturing improvements and a broad indication set have driven Breyanzi to top market share in several countries.
Breyanzi's safety profile enables outpatient administration, freeing up inpatient capacity and supporting further growth.
Seasonality affects CAR T utilization, but ongoing label updates and outpatient expansion are expected to drive long-term growth.
The company is proactively building physician networks and ecosystems to support CAR T adoption in both hematology and immunology.
Next Bristol-Myers Squibb Company earnings date

Next Bristol-Myers Squibb Company earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage